Biotech Values

[biophud]

Dew, Thanks for your opinions on DNDN on the IMCL board.

I would like opinions on DYAX as an investment. My Pros and Cons are listed below.

Pro’s:
My bet is that DX-88 will be approved. HAE is a small indication, but it may be enough to be material to DYAX.
DX-88-->Strong partner with Genzyme.
A fully human phage-antibody company with a small market cap.
One of the cheapest fully human phage-antibody companies by market cap (to the best of my knowledge).
Possibility of royalties on future antibody sales-->Many of Imclone’s phage-antibodies were generated using DYAX phage display.
DX-88 for CABG(?)
Stock is at a relative low.

Con’s:
Could DYAX survive a delay or demise of DX-88?
Basically a one-product company.
Other than DX-88, a limited near-term pipeline.

Any opinions would be appreciated.
biophud